Working… Menu

A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01998841
Recruitment Status : Active, not recruiting
First Posted : December 2, 2013
Last Update Posted : July 6, 2021
Banner Alzheimer's Institute
National Institute on Aging (NIA)
Information provided by (Responsible Party):
Genentech, Inc.